Following a pharma partners agreement, Catalent has commenced supply to big pharma, Otsuka Pharmaceutical of Abilify OD Tablets which utilize Catalent’s Zydis fast dissolve drug delivery technology.
Otsuka has developed Abilify OD for the treatment of schizophrenia and improvement of manic symptoms associated with bipolar disorder.
Additionally, to support the increasing demand for Zydis ODT formulations from the Japanese market, Catalent intends to make multi-million dollar investments to its Zydis ODT operations in Swindon, UK.
For further deal information visit Current Agreements (subscription required)
Read: more on partnering deals in pharma, biotech, life science partnering deal news, insights and glossary
Read: Big pharma deal news- latest deal news for top 50 pharma / big pharma companies
Report: Practical Guide to Finding Partners
Report: Partnering Deals and Alliances with Otsuka
View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity